TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04711369

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erbium:Yag laser
Description: Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2.~All sensitive/painful areas of the introitus will be treated, using 1-3 repetitions.~In postmenopausal women with signs of atrophy, additional irradiation of the vaginal wall will be performed.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Erbium:Yag laser
Description: Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same procedures. However, a specially devised placebo probe with a steel shutter, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic irradiation. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the normal probe. The treating physician will not be aware of the study allocation and the type of probe in use.
Study: NCT04606706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile health nutrition education intervention
Description: Nutrition education will be given through mobile phone
Study: NCT05958953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction of Labor IoL
Description: Center-specific IOL protocols, based on international guidelines, will be used.
Study: NCT06249698

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: meal replacements and supplements
Description: Consumed daily: 2 Nutrimeal Active meal replacement shake, 1 electrolyte replacement drink, 3 metabolism + supplements, 1 whole food meal, and whole food snacks consisting of fruits and vegetables. 1200-1600 calories per day
Study: NCT06795165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxidectin 2 MG Oral Tablet
Description: active medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin 2 MG Oral Tablet
Description: active medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo pills
Study: NCT05623787

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole-body diffusion-weighted magnetic resonance imaging
Description: See arm description.
Study: NCT05457153

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Well-Being Process Program (WEBEPROP)
Description: Technology-Based Well-Being Process Program (WEBEPROP)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Well-Being Process Program (WEBEPROP)
Description: Technology-Based Well-Being Process Program (WEBEPROP)
Study: NCT06088953

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VRB test
Description: V1 (inclusion) : VRB test for detecting speech comprehension disorders in noise.~V2 (3 months) : all patients ( independent of the result of the VRB test) will be invited to attend a hearing test within 3 months in order to confirm the diagnosis of deafness by means of a tone audiometry and an ENT medical consultation.
Study: NCT06179134

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: The main objective of GMT intervention are to train individuals to periodically STOP what they are doing, attend to task goals, evaluate their performance and monitor or check outcomes as they proceed (Levine \& Stamenova, 2017).
Study: NCT06795165

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pills
Study: NCT06794125

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Hypofractionated, dose-escalated, esophageal-sparing intensity modulated radiation therapy
Study: NCT05377983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender oil inhalation will be performed by placing two drops of 2% lavender oil on a 5x5 cm sterile gauze cloth and asking the patient to smell it for three to five minutes
Description: During the hospitalization period after CABG surgery, 2% lavender oil (Lavandula angustifolia) inhalation will be applied to the intervention group three times a day.
Study: NCT05755048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502)
Description: Experimental: FS-1502 Dosage form: lyophilized powder Specification: 30 mg/vial Dose: 2.3 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
Description: Active Comparator: Trastuzumab Emtansine (T-DM1) Trade name: Kadcyla Dosage form: lyophilized powder Specification: 100 mg/vial Dose: 3.6 mg/kg, once every 3 weeks, 21 days as a cycle; Method of administration: intravenous drip (this drug has been approved for marketing. Please refer to the package insert for details).
Study: NCT05631197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biorepair Total Protection Plus + desensitizing enamel-repair shock treatment
Description: Domiciliary use twice a day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensodyne Repair & Protect
Description: Domiciliary use twice a day
Study: NCT06794125

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: standard of care palliative thoracic radiotherapy using volumetric modulated arc therapy/intensity-modulating radiotherapy
Study: NCT06791265

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Eminectomy
Description: The patients will be subjected to computer-guided osteotomy utilizing a virtually preplanned cutting guide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free hand Eminectomy
Description: The patients will be subjected to a free-hand Eminectomy utilizing the routine surgical technique
Study: NCT06797765

Intervention type: DEVICE
Intervention: OCTA
Description: Optical Coherence Tomography Angiography

Intervention type: DEVICE
Intervention: OCTA
Description: Optical Coherence Tomography Angiography
Study: NCT06795048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Participants will receive 6-mg faricimab intravitreal (IVT) injections in the study eye according to the dosing regimen for the study arm to which they are randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Participants will receive 6-mg faricimab intravitreal (IVT) injections in the study eye according to the dosing regimen for the study arm to which they are randomized.
Study: NCT06793657

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: computed tomography and poppy seed
Description: comparison of both interventions
Study: NCT06794866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Intramuscular Injections
Study: NCT05150873

Intervention type: OTHER
Intervention: CTA evaluation
Description: Any pre-operattive CTA of the patients of the cohort will be carefully evaluated to determine the theoric anatomical feasibility of an off the shelf Endograft, particularly in patients with an angulated and short aortic neck
Study: NCT06794866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Intramuscular Injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Intramuscular Injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Intramuscular Injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular Injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular Injections
Study: NCT06796530

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET)
Description: Participants undergo a CPET on a stationary bike, measuring gas exchange, ECG, and other parameters. The protocol includes 3 minutes of cycling at a constant load (body weight/2 in Watts), followed by a maximal effort test with an incremental load (Ramp protocol body weight (kg) / 4 in Watts per minute).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-intensity circuit training
Description: The patients will undergo a 10-minute warm-up, followed by \~30 high intensity exercise circuit.
Study: NCT06794957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL8326 tablets
Description: 10mg/tablet;Oral administration, once daily.
Study: NCT06796868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW117 Tablets
Description: GW117 Tablets 20mg orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW117 Tablets
Description: GW117 Tablets 20mg\*2 orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW117 Tablets
Description: GW117 Tablets 20mg\*3 orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo orally once a day
Study: NCT06796569

Intervention type: DIAGNOSTIC_TEST
Intervention: systemic immune inflammatory index
Description: Systemic immune inflammatory index (SII) is a combination of three hematological parameters (platelets, neutrophils, and lymphocytes) and it is calculated using the following formula: SII = (neutrophil count × platelet count)/lymphocyte count.

Intervention type: DIAGNOSTIC_TEST
Intervention: systemic immune inflammatory index
Description: Systemic immune inflammatory index (SII) is a combination of three hematological parameters (platelets, neutrophils, and lymphocytes) and it is calculated using the following formula: SII = (neutrophil count × platelet count)/lymphocyte count.

Intervention type: DIAGNOSTIC_TEST
Intervention: systemic immune inflammatory index
Description: Systemic immune inflammatory index (SII) is a combination of three hematological parameters (platelets, neutrophils, and lymphocytes) and it is calculated using the following formula: SII = (neutrophil count × platelet count)/lymphocyte count.
Study: NCT06788704

Intervention type: DRUG
Intervention: Tadalafil 5mg
Description: Patient recive tadalafil 5mg once daily early post turp

Intervention type: DRUG
Intervention: Placebo
Description: Patient recive placebo once daily early post turp
Study: NCT06793904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor Letrozole
Description: 2.5 mg tab twice daily from the 3rd day of the cycle for 5 days
Study: NCT04929899

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Bright Ideas - CIN Training
Description: Bright IDEAS is a validated problem-solving skill training intervention.
Study: NCT06796972

Intervention type: OTHER
Group type: OTHER
Intervention: Semi-structured interviews with a psychologist
Description: Semi-directed interviews using an interview guide on different themes
Study: NCT06794372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-FAPI-46 PET/CT
Description: \[68Ga\]Ga-FAPI-46 PET/CT
Study: NCT06791382

Intervention type: DIAGNOSTIC_TEST
Intervention: AI-Based Diagnostic and Prognostic Model
Description: This intervention involves an AI system that integrates multimodal data, including patient medical history, laboratory test results, clinical observations, and treatment data, to predict the risk of hospital-acquired infections (HAIs). The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of patients at risk for infections. By analyzing historical health data, the model aims to predict potential infection developments, improving early detection, prevention strategies, and patient outcomes in hospital settings.

Intervention type: DIAGNOSTIC_TEST
Intervention: AI-Based Diagnostic and Prognostic Model
Description: This intervention involves an AI system that integrates multimodal data, including patient medical history, laboratory test results, clinical observations, and treatment data, to predict the risk of hospital-acquired infections (HAIs). The system uses deep learning algorithms to provide real-time, accurate predictions, enabling early identification of patients at risk for infections. By analyzing historical health data, the model aims to predict potential infection developments, improving early detection, prevention strategies, and patient outcomes in hospital settings.
Study: NCT04520217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Imipramine Cream
Description: 4% Imipramine Cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Base Cream
Description: Base Cream
Study: NCT06793618

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Z-track technique
Description: In this method, the neonates are in supine position, the skin is moved and held from the injection site 2 to 3 cm to the side or downward using the non- dominant hand, to ensure that blood vessel wasn't penetrated aspiration on the syringe must perceive the injection and then the medication is to be injected slowly. Researcher assistant that is unaware of the injection method performs the recording of the pain intensity and leakage diameter on the observation form.
Study: NCT06066021

Intervention type: OTHER
Group type: OTHER
Intervention: health educational sessions in diabetic patients type 2.
Description: Professionals from different areas will be invited to carry out the sessions at Visit 2, namely on: mental health, physical activity, nutrition and self-care.
Study: NCT06153420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-103
Description: CIN-103 BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-103
Description: CIN-103 BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for CIN-103 BID
Study: NCT05295121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221 100 mg tablets
Description: XC221, 3 discrete doses separated by 7-day wash-out periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221 100 mg tablets
Description: XC221, 3 discrete doses separated by 7-day wash-out periods
Study: NCT05997914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling Intervention
Description: Participants assigned to the intervention group will watch videos presenting stories of African American patients about their experiences with using anticoagulation or blood thinners throughout a 90-day period.
Study: NCT06068478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qingzhu Granules
Description: During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules.Oral administration, 1 sack (6g) per time, 3 times daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Qingzhu Granules Placebo
Description: During the 72-hour treatment period, participants will receive 9 sacks of Qingzhu granules Placebo.Oral administration, 1 sack (6g) per time, 3 times daily.
Study: NCT05301257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group SOSteniamoci
Description: Intervention based on cognitive behavioural therapy principles and culturally adapted to Italian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
Study: NCT05556057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindfulness meditation(MM)
Description: Participants will be provided with a unique invitation code that will allow them to download and use the free research version of the Mindfulness Coach app that is designed to deliver mindfulness training developed by the Veteran Affairs' National Center for PTSD.The app is tailored to users who may be skeptical about meditation practices by providing simple instructions and brief meditation exercises. The app offers written information about mindfulness as well as 12 audio-guided meditations each lasting 8-13 minutes, with an average length of 10 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (active control)
Description: Participants will be asked to download and use the free TED Talk app.Each participant's account will include a list of over 80 TED Talks related to the six broad categories of sleep, nutrition, mood, relationships, chronic pain, and health behaviors. These talks range from 4 to 18 minutes and were reviewed/selected by the investigator team. The research coordinator(RC) will instruct them to watch or listen to these videos for ≥ 10 minutes daily for 6 days per week. The RC will ask participants to complete weekly logs of their TED Talk app use
Study: NCT04497857

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coordinated Specialty Care (CSC)
Description: CSC care is an evidenced-based, comprehensive specialty care programs for young people in the initial phases of psychotic disorders

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinated Specialty Care (CSC)
Description: CSC care is an evidenced-based, comprehensive specialty care programs for young people in the initial phases of psychotic disorders
Study: NCT05866029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Active Comparator: 60mg of Denosumab treatment by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Active Comparator: 60mg of Denosumab treatment by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide was sequentially treated with Denosumab
Study: NCT05647772

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UseIt! App
Description: The UseIt! app is a parenting app with evidence-based parent management content. The app runs on both Android and iOS devices. It includes a digital library of parent management skills, a trouble-shooting guide, a behavior diary, a point counter, and a skills-alarm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UseIt! App
Description: The UseIt! app is a parenting app with evidence-based parent management content. The app runs on both Android and iOS devices. It includes a digital library of parent management skills, a trouble-shooting guide, a behavior diary, a point counter, and a skills-alarm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coach
Description: The coach is be a bachelor's level paraprofessional with a degree in psychology or an allied discipline (e.g., social work) who provides support to parents. The coach will provide motivation and accountability but will not provide therapeutic/clinical support. The primary goal of the coach is to increase participant engagement with the UseIt! mHealth system.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SmilingMind App
Description: The control app is a mindfulness app called SmilingMind. It is available for both Android and iOS devices.
Study: NCT05772455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZB-0004
Description: Part 1a: 100mg BID, 150mg BID, and 200mg BID of XZB-0004 are planned to be evaluated, and the possibility of exploring higher or lower doses is not ruled out. Continuous administration of XZB-0004 for 21 days is a treatment cycle. Part 1b: XZB-0004 in combination with Penpulimab in subjects with advanced NSCLC or solid tumors, starting at a dose level down from the RP2D of XZB-0004 monotherapy- cohort 1: Advanced or metastatic NSCLC with advanced disease progression after treatment with PD-1 or PD-L1 inhibitors; cohort 2: Advanced or metastatic NSCLC with advanced disease progression after platinum-containing chemotherapy without prior use of any immunocheckpoint inhibitors; cohort3: Advanced or metastatic solid tumors that cannot be radically cured by surgery or local therapy, including but not limited to urothelial carcinoma, melanoma, etc. Subjects had disease progression since last antitumor therapy, no availability or intolerance or refusal of standard therapy.
Study: NCT05083403

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcumenTM HPI Software Feature
Description: The AcumenTM HPI Feature Software provides the clinician with physiological insight into a patient's likelihood of trending toward a hypotensive event. The AcumenTM HPI Feature Software suite is enabled by the minimally invasive Acumen IQ sensor.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-protocolized Standard of Care
Description: Non-protocolized standard of care to treat subjects
Study: NCT06794723

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-strain probiotic plus prebiotic natural health product
Description: The investigational product is a 5-strain probiotic plus prebiotic natural health product for patients with Type 2 diabetes. Other ingredients include oligofructose, grape food color, magnesium stearate, silica and a delayed release capsule.~Recommended storage is in a refrigerated environment at approximately 4°C. The product should not be frozen. It is recommended that the product be used within 2 months after opening the bottle. Participants are asked to take 2 capsules daily with food, 1 in the morning and 1 in the evening. There is ≥ 2 billion AFU per dose in total.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingredients include oligofructose, grape food color, magnesium stearate, silica and a delayed release capsule.~Recommended storage is in a refrigerated environment at approximately 4°C. The product should not be frozen. It is recommended that the product be used within 2 months after opening the bottle. Participants are asked to take 2 capsules daily with food, 1 in the morning and 1 in the evening.
Study: NCT06797219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy for Intraventricular Hemorrhage of Prematurity
Description: The experimental arm will be administered treated with the study device. It will be 10 mW/cm\^2 of 650nm laser through use of a novel laser device given for 5 minutes twice daily for 12 days.
Study: NCT06794541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline 2mg/kg
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline 2mg/kg
Description: intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline 1.5mg/kg
Description: intravenous (IV) infusion
Study: NCT06793813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cadonilimab，bevacizumab，docetaxel
Description: Patients receive Cadonilimab IV over 90 minutes on day 1. Patients also receive bevacizumab 7.5mg/kg IV on day 1 and docetaxel 60-75 mg/m2 IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Study: NCT06020378

Intervention type: DRUG
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine was administered during pregnancy
Study: NCT06797518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iptacopan
Description: LNP023 oral capsule 200 mg b.i.d